ArticleArXiv2025
Stereotactic Arrhythmia Radioablation for Refractory Ventricular Tachycardia: A Narrative Review and Exploratory Pooled Analysis of Clinical Outcomes and Toxicity.
Article in ArXiv, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
9 authors.
Funding
Abstract
Purpose: Stereotactic arrhythmia radioablation (STAR) is a non-invasive salvage therapy for refractory ventricular tachycardia (VT), especially in patients ineligible for catheter ablation. This narrative review and pooled analysis evaluates the safety, efficacy, and technical characteristics of STAR, integrating preclinical studies, case reports, case series, and clinical trials. Methods and Materials: A comprehensive review identified 86 studies published between 2015 and 2025, including 12 preclinical studies, 49 case reports, 18 case series, and 7 clinical trials. Study-level data were extracted for pooled analysis of 6- and 12-month mortality, VT burden reduction, and grade 3+ acute toxicities. Subgroup analyses were performed by delivery modality, age, left ventricular ejection fraction (LVEF), and cardiomyopathy type. Results: Pooled mortality was 16% (95% CI: 11-20%) at 6 months and 33% (95% CI: 27-38%) at 12 months. VT burden reduction at 6 months averaged 75% (95% CI: 73-77%) but showed substantial heterogeneity (I Conclusions: STAR is a promising salvage therapy with favorable acute safety and efficacy. Outcome heterogeneity and inconsistent reporting highlight the need for standardized definitions, dosimetric protocols, and longer-term follow-up. Prospective trials and real-world registries are critical for refining STAR's role in VT management.
Indexed as
Identifiers
39975451PMC11838787What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.